Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388417 | 0.89 | TSHR (0.55) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL16087778 | 0.88 | FOLH1 (0.45) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL8049313 | 0.86 | CA1 (0.39) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL3237660 | 0.84 | KMT2A (0.48) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL6363454 | 0.83 | CA1 (0.42) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL9509840 | 0.83 | CA1 (0.62) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL18264428 | 0.82 | TSHR (0.52) | SLC1A1TSHRCA1CA2 | |
| SCHEMBL579709 | 0.82 | CA1 (0.50) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL9814818 | 0.82 | SLC1A1 (0.47) | SLC1A1TSHRCA1CA2KMT2A | |
| SCHEMBL20464696 | 0.82 | SLC1A1 (0.47) | SLC1A1TSHRCA1CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4125556-A | Synthesis of 11-deoxyprostaglandins | THE DOW CHEMICAL COMPANY (US) | 1978-11-14 | — | — | US | claimed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-9550745-B2 | Method for preparing 4-aminobut-2-enolides | BAYER CROPSCIENCE AG (DE) | 2017-01-24 | — | — | US | disclosed |
| EP-2744499-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20150183763-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9062070-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-8846746-B2 | Pyrazole compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-07-24 | — | — | US | disclosed |
| EP-2744499-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2621545-A1 | APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2007049061-A2 | CONJUGATES OF SEMAPHORIN PEPTIDES AS IMAGING AGENTS FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2007-05-03 | — | — | WO | disclosed |
| CN-1901894-A | Inhibitor imaging agents | GE HEALTHCARE LTD (GB) | 2007-01-24 | — | — | CN | disclosed |
| EP-1682113-A1 | INHIBITOR IMAGING AGENTS | GE Healthcare Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049005-A1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-4532081-A | 2-(6'-cyano-2'-hexynyl)-2-(b,b,b -trichlorocarboethoxy)-3-carbomethoxy cyclopentanone | THE DOW CHEMICAL COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| US-4447636-A | TRANS-2-B,B,B-TRICHLOROCARBOETHOXY-3 -CARBOMETHOXYCYCLOPENTANONE INTERMEDIATE | THE DOW CHEMICAL COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| US-4146553-A | Intermediates for synthesizing 11-deoxyprostaglandins | THE DOW CHEMICAL COMPANY (US) | 1979-03-27 | — | — | US | disclosed |
| US-4146553-A | Intermediates for synthesizing 11-deoxyprostaglandins | THE DOW CHEMICAL COMPANY (US) | 1979-03-27 | — | — | US | disclosed |
| US-4125556-A | Synthesis of 11-deoxyprostaglandins | THE DOW CHEMICAL COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4125556-A | Synthesis of 11-deoxyprostaglandins | THE DOW CHEMICAL COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | SLC1A1 2734/4885TSHR 2282/4885CA1 4140/4885 |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | SLC1A1 322/4885TSHR 1586/4885CA1 2910/4885 |
| US-20150183763-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC34A1 | SLC1A1 209/4885TSHR 2374/4885CA1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.